Endophthalmitis outbreak associated with repackaged bevacizumab

Emerg Infect Dis. 2015 Jan;21(1):171-3. doi: 10.3201/eid2101.141040.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / adverse effects*
  • Angiogenesis Inhibitors / therapeutic use
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Bevacizumab
  • Carnobacteriaceae / isolation & purification
  • Disease Outbreaks*
  • Drug Contamination
  • Endophthalmitis / epidemiology*
  • Endophthalmitis / microbiology
  • Female
  • Georgia / epidemiology
  • Gram-Positive Bacterial Infections / epidemiology*
  • Gram-Positive Bacterial Infections / microbiology
  • Gram-Positive Bacterial Infections / transmission
  • Humans
  • Indiana / epidemiology
  • Macular Degeneration / drug therapy
  • Male
  • Middle Aged
  • Off-Label Use
  • Vitreous Body / microbiology

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab